Compile Data Set for Download or QSAR
Report error Found 512 Enz. Inhib. hit(s) with all data for entry = 11949
TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 664524BDBM664524(US20240109930, Example 2.1.74.A | (2R,3R,4S,5R,6R)...)
Affinity DataIC50: 10nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 664519BDBM664519((2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3- difluoropheny...)
Affinity DataIC50: 10nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 664585BDBM664585((2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3- difluoropheny...)
Affinity DataIC50: 10nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 664546BDBM664546(US20240109930, Example 2.1.89.A | (2R,3R,4S,5R,6R)...)
Affinity DataIC50: 10nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 664557BDBM664557(US20240109930, Example 3.1.66.C | (2R,3R,4S,5R,6R)...)
Affinity DataIC50: 20nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 664432BDBM664432(US20240109930, Example 1.1.19. | (2R,3R,4S,5R,6R)-...)
Affinity DataIC50: 20nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 664491BDBM664491((2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3-difluorophenyl...)
Affinity DataIC50: 20nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 664562BDBM664562((2R,3R,4S,5R,6R)-4-(4-(4-bromo-2,3- difluorophenyl...)
Affinity DataIC50: 20nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 664436BDBM664436(US20240109930, Example 1.1.23. | (2R,3R,4S,5R,6R)-...)
Affinity DataIC50: 20nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 664617BDBM664617(US20240109930, Example 1.2.37. | tert-butyl (4-(1-...)
Affinity DataIC50: 20nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 664483BDBM664483((2R,3R,4S,5R,6R)-4-(4-(4-bromo-2,3-difluorophenyl)...)
Affinity DataIC50: 20nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 664546BDBM664546(US20240109930, Example 2.1.89.A | (2R,3R,4S,5R,6R)...)
Affinity DataIC50: 20nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 664549BDBM664549((2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3-difluorophenyl...)
Affinity DataIC50: 20nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 664462BDBM664462(US20240109930, Example 2.1.23. | (2R,3R,4S,5R,6R)-...)
Affinity DataIC50: 20nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 664529BDBM664529((2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3- difluoropheny...)
Affinity DataIC50: 20nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 664592BDBM664592((2R,3R,4S,5R,6R)-6-((1-(3-(difluoromethyl)oxetan- ...)
Affinity DataIC50: 20nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 664534BDBM664534((2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3- difluoropheny...)
Affinity DataIC50: 20nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 664598BDBM664598((2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3-difluorophenyl...)
Affinity DataIC50: 20nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 664537BDBM664537(US20240109930, Example 2.1.80.A | US20240109930, E...)
Affinity DataIC50: 20nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 664595BDBM664595((2R,3R,4S,5R,6R)-4-(4-(4-bromo-2,3- difluorophenyl...)
Affinity DataIC50: 20nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 664532BDBM664532(US20240109930, Example 2.1.78.A | (2R,3R,4S,5R,6R)...)
Affinity DataIC50: 20nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 664596BDBM664596((2R,3R,4S,5R,6R)-4-(4-(4-bromo-2,3- difluorophenyl...)
Affinity DataIC50: 20nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 664511BDBM664511((2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3- difluoropheny...)
Affinity DataIC50: 20nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 664510BDBM664510((2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3- difluoropheny...)
Affinity DataIC50: 20nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 664577BDBM664577((2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3- difluoropheny...)
Affinity DataIC50: 20nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 664509BDBM664509((2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3- difluoropheny...)
Affinity DataIC50: 20nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 664572BDBM664572((2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl...)
Affinity DataIC50: 20nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 664518BDBM664518((2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3- difluoropheny...)
Affinity DataIC50: 20nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 664520BDBM664520(US20240109930, Example 2.1.68.A | (2R,3R,4S,5R,6R)...)
Affinity DataIC50: 20nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 664450BDBM664450(US20240109930, Example 2.1.13. | (2R,3R,4S,5R,6R)-...)
Affinity DataIC50: 20nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 664580BDBM664580((2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3- difluoropheny...)
Affinity DataIC50: 20nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 664559BDBM664559((2R,3R,4S,5R,6R)-4-(4-(4-bromo-2,3- difluorophenyl...)
Affinity DataIC50: 30nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 664561BDBM664561((2R,3R,4S,5R,6R)-4-(4-(4-bromo-2,3- difluorophenyl...)
Affinity DataIC50: 30nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 664496BDBM664496((2R,3R,4S,5R,6R)-2-(hydroxymethyl)-5-methoxy-6-((1...)
Affinity DataIC50: 30nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 664560BDBM664560((2R,3R,4S,5R,6R)-4-(4-(4-bromo-2,3- difluorophenyl...)
Affinity DataIC50: 30nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 664624BDBM664624((2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3-difluorophenyl...)
Affinity DataIC50: 30nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 664426BDBM664426(US20240109930, Example 1.1.13. | (2R,3R,4S,5R,6R)-...)
Affinity DataIC50: 30nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 664618BDBM664618(US20240109930, Example 1.2.38. | (2R,3R,4S,5R,6R)-...)
Affinity DataIC50: 30nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 664493BDBM664493((2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3-difluorophenyl...)
Affinity DataIC50: 30nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 664428BDBM664428(US20240109930, Example 1.1.15. | (2R,3R,4S,5R,6R)-...)
Affinity DataIC50: 30nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 664492BDBM664492((2R,3R,4S,5R,6R)-6-((1-(2-oxabicyclo[2.1.1]hexan-4...)
Affinity DataIC50: 30nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 664566BDBM664566((2R,3R,4S,5R,6R)-4-(4-(4-bromo-2,3- difluorophenyl...)
Affinity DataIC50: 30nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 664440BDBM664440(US20240109930, Example 1.1.27. | (2R,3R,4S,5R,6R)-...)
Affinity DataIC50: 30nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 664504BDBM664504((2R,3R,4S,5R,6R)-4-(4-(4-bromo-2,3-difluorophenyl)...)
Affinity DataIC50: 30nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 664629BDBM664629((2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3-difluorophenyl...)
Affinity DataIC50: 30nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 664564BDBM664564((2R,3R,4S,5R,6R)-4-(4-(4-bromo-2,3- difluorophenyl...)
Affinity DataIC50: 30nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 664542BDBM664542(US20240109930, Example 2.1.88.A | (2R,3R,4S,5R,6R)...)
Affinity DataIC50: 30nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 664607BDBM664607(4-(1-((2R,3R,4S,5R,6R)-2-((1-(1-(difluoromethyl)cy...)
Affinity DataIC50: 30nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 664542BDBM664542(US20240109930, Example 2.1.88.A | (2R,3R,4S,5R,6R)...)
Affinity DataIC50: 30nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 664608BDBM664608(2,3-difluoro-4-(1-((2R,3R,4S,5R,6R)-2-((1-((3R*,4S...)
Affinity DataIC50: 30nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384well plates are supplemented with 22.8 μL/well of biotinylate...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
US Patent

Displayed 1 to 50 (of 512 total ) | Next | Last >>
Jump to: